Performance of host-response biomarkers to risk-stratify children with pneumonia in Bhutan

dc.contributor.authorJullien, Sophie
dc.contributor.authorRichard-Greenblatt, Melissa
dc.contributor.authorNgai, Michelle
dc.contributor.authorLhadon, Tenzin
dc.contributor.authorSharma, Ragunath
dc.contributor.authorDema, Kumbu
dc.contributor.authorKain, Kevin C.
dc.contributor.authorBassat Orellana, Quique
dc.date.accessioned2024-11-25T15:33:40Z
dc.date.available2024-11-25T15:33:40Z
dc.date.issued2022-12-01
dc.date.updated2024-11-25T15:33:41Z
dc.description.abstractPneumonia is the leading cause of post-neonatal death amongst children under five years of age; however, there is no simple triage tool to identify children at risk of progressing to severe and fatal disease. Such a tool could assist for early referral and prioritization of care to improve outcomes and enhance allocation of scarce resources. We compared the performance of inflammatory and endothelial activation markers in addition to clinical signs or scoring scales to risk-stratify children hospitalized with pneumonia at the national referral hospital of Bhutan with the goal of predicting clinical outcome. Of 118 children, 31 evolved to a poor prognosis, defined as either mortality, admission in the paediatric intensive care unit, requirement of chest drainage or requirement of more than five days of oxygen therapy. Soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) was the best performing biomarker and performed better than clinical parameters. sTREM-1 levels upon admission had good predictive accuracy to identify children with pneumonia at risk of poor prognosis. Our findings confirm that immune and endothelial activation markers could be proactively used at first encounter as risk-stratification and clinical decision-making tools in children with pneumonia; however, further external validation is needed.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn0163-4453
dc.identifier.pmid36243198
dc.identifier.urihttps://hdl.handle.net/2445/216725
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.jinf.2022.10.010
dc.relation.ispartofJournal of Infection, 2022, vol. 85, num.6, p. 634-643
dc.relation.urihttps://doi.org/10.1016/j.jinf.2022.10.010
dc.rightscc-by-nc-nd (c) Jullien, Sophie et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationPneumònia
dc.subject.classificationInfants
dc.subject.classificationAvaluació del risc per la salut
dc.subject.classificationMarcadors bioquímics
dc.subject.classificationBhutan
dc.subject.otherPneumonia
dc.subject.otherChildren
dc.subject.otherHealth risk assessment
dc.subject.otherBiochemical markers
dc.subject.otherBhutan
dc.titlePerformance of host-response biomarkers to risk-stratify children with pneumonia in Bhutan
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
870212.pdf
Mida:
1.73 MB
Format:
Adobe Portable Document Format